Corticosteroids in the Treatment of Community-Acquired Pneumonia in Adults: A Meta-Analysis

Wei Nie1*, Yi Zhang2*, Jinwei Cheng3*, Qingyu Xiu1*

1 Department of Respiratory Disease, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China, 2 Department of Gastroenterology, The 452nd Military Hospital of China, Chengdu, Sichuan, China, 3 Department of Ophthalmology, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China

Abstract

Background: The benefit of corticosteroids in community-acquired pneumonia (CAP) remains controversial. We did a meta-analysis to include all the randomized controlled trials (RCTs) which used corticosteroids as adjunctive therapy, to examine the benefits and risks of corticosteroids in the treatment of CAP in adults.

Methods: Databases including Pubmed, EMBASE, the Cochrane controlled trials register, and Google Scholar were searched to find relevant trials. Randomized and quasi-randomized trials of corticosteroids treatment in adult patients with CAP were included. Effects on primary outcome (mortality) and secondary outcomes (adverse events) were accessed in this meta-analysis.

Results: Nine trials involving 1001 patients were included. Use of corticosteroids did not significantly reduce mortality (Peto odds ratio [OR] 0.62, 95% confidence interval [CI] 0.37–1.04; P = 0.07). In the subgroup analysis by the severity, a survival benefit was found among severe CAP patients (Peto OR 0.26, 95% CI 0.11–0.64; P = 0.003). In subgroup analysis by duration of corticosteroids treatment, significant reduced mortality was found among patients with prolonged corticosteroids treatment (Peto OR 0.51, 95% CI 0.26–0.97; P = 0.04; I² = 37%). Corticosteroids increased the risk of hyperglycemia (Peto OR 2.64, 95% CI 1.68–4.15; P < 0.0001), but without increasing the risk of gastroduodenal bleeding (Peto OR 1.67, 95% CI 0.41–6.80; P = 0.47) and superinfection (Peto OR 1.36, 95% CI 0.65–2.84; P = 0.41).

Conclusion: Results from this meta-analysis did not suggest a benefit for corticosteroids treatment in patients with CAP. However, the use of corticosteroids was associated with improved mortality in severe CAP. In addition, prolonged corticosteroids therapy suggested a beneficial effect on mortality. These results should be confirmed by future adequately powered randomized trials.

Introduction

Community-acquired pneumonia (CAP) is a common and serious infectious disease associated with high morbidity and mortality. It is the sixth leading cause of death and the most common infectious cause of death worldwide [1]. Despite effective antibiotic therapy, about 12–36% patients admitted to the intensive care unit (ICU) with severe CAP die within a short time [2]. Therefore, the development of an efficacious treatment has important implications for reducing the high mortality.

During infectious pneumonia, inflammatory cytokines, such as interleukin (IL)-6, IL-8 and IL-10 acted as acute phase proteins [3]. A recent study showed that the excess of IL-6 and IL-10 was associated with a high mortality rate in CAP [4]. Corticosteroids are the most effective and widely used anti-inflammatory drugs. An early study demonstrated the association of glucocorticoids with antibiotics attenuated local inflammatory response and decreased bacterial burden in the experimental model of severe pneumonia [5]. In a mouse pneumonia model, Li et al. [6] found that hydrocortisone decreased inflammatory response significantly. In addition, Salluh et al. [7] reported that relative adrenal insufficiency occurred in most of the patients with severe CAP, suggesting underlying benefits of corticosteroids treatment in these patients. Taken together, these facts indicated a potential beneficial effect of corticosteroids in pneumonia.

Recently, a multicenter randomized controlled trial (RCT) performed by Confalonieri et al. [8] demonstrated that hydrocortisone treatment in severe CAP was associated with a significant reduction in mortality. A retrospective study conducted by Garcia-Vidal et al. [9] found that mortality decreased in the patients who received systemic steroids along with antibiotic treatment for severe CAP. Moreover, results from a systematic review showed...
that administration of corticosteroids in patients with CAP was associated with a lower mortality [10]. However, these findings were not confirmed in the subsequent larger RCTs [11–14]. Another recent retrospective study also showed that adjunctive therapy with corticosteroids did not influence the mortality rate [15]. Furthermore, results from a meta-analysis found that participants receiving corticosteroids displayed no significant differences in mortality compared with placebo [16]. Consequently, the benefits of corticosteroids treatment in CAP are still uncertain.

The aim of this meta-analysis was to evaluate the efficacy and safety of corticosteroids adjunctive therapy in the treatment of CAP in adults.

Materials and Methods

This meta-analysis was performed according to a predetermined protocol described in the following paragraph, using standard systematic review techniques, as outlined by the Cochrane Handbook for Systematic Reviews of Interventions and PRISMA Statement [17,18].

Eligibility Criteria and Outcome Measures

Studies fulfilling the following selection criteria were included in this meta-analysis: (1) study design: RCTs, including quasi-RCTs; (2) population: adult patients with CAP; (3) intervention: corticosteroids adjunctive therapy in CAP; (4) comparison intervention: placebo or standard treatment; and (5) outcome variables: mortality. Studies were excluded if: studies enrolled pediatric patients or nosocomial pneumonia patients.

The primary outcome measure was mortality. Secondary outcome measures included: hyperglycemia, gastrroduodenal bleeding, and superinfection.

Information Sources and Search

A PubMed, EMBASE and the Cochrane controlled trials register search identified RCTs of corticosteroids adjunctive therapy versus control participants published up to May 2012 in any language literature. The electronic search strategy included the terms “steroids”, “glucocorticoids”, “corticosteroids”, “hydrocortisone”, “prednisone”, “methylprednisolone”, “dexamethasone” and “community-acquired pneumonia”. We also searched the reference lists of original reports and systematic review of studies involving CAP to identify studies not yet included in the computerized databases. In addition, we reviewed the cited lists of eligible trials by Google Scholar to ensure that all appropriate studies were included.

Study Selection

A total of 772 studies were retrieved, and the process of identifying relevant trials is shown in Figure 1. Among the 772 initially potentially relevant studies, one study was searched from Google Scholar through reviewing the cited lists of eligible trials [14], and three studies were identified from reviews by hand searched [19–21]. 748 studies were excluded because of irrelevant, review or commentary articles. After full-text articles assessed for eligibility, fifteen studies were excluded because four studies enrolled pediatric patients and the other eleven studies were non-RCTs. Subsequently, nine RCTs were included in qualitative synthesis and quantitative synthesis.

Data Collection Process

Two authors independently reviewed full manuscripts of eligible trials, and the relevant data were extracted into predesigned data collection forms. We verified accuracy of data by comparing collection forms from each reviewer. Any discrepancy was resolved by discussion or a third author would assess these articles. The following data were collected from each study: first author, year of publication, study design, location, sample size, participant demographics, corticosteroids doses, duration of corticosteroids treatment and outcome variables. Authors of the included studies were contacted via E-mail if further study details were needed.

Qualitative Assessment

Methodological quality assessment was independently performed by two of the authors, and any disagreement was resolved by consensus. Risk of bias was evaluated as high, low, or unclear using the Cochrane Risk of Bias Tool for RCTs [17].

Statistical Analysis

The outcome measure was assessed in an intention-to-treat (ITT) manner. Peto method works well when intervention effects are small, events are not particularly common and the study has similar numbers in two groups [22]. Therefore, mortality and adverse events were analyzed using the Peto method to calculate odds ratio (OR) and 95% confidence interval (CI). Heterogeneity was assessed using the I² test statistic and classified as low (≤25%), moderate (25–50%), and high (>50%). Subgroup analysis was performed by the severity of CAP and the duration of corticosteroids treatment. We defined the prolonged course as corticosteroids treatment for more than 5 days [23]. Prespecified sensitivity analyses are conducted to determine the influence of statistical models (the fixed-effects model and the random-effects model) on effect size. Graphic exploration with funnel plot was used to evaluate the publication bias visually. The Egger’s test [24] was used to assess publication bias statistically. A P value <0.05 was considered statistically significant. All statistical tests were performed by using the RevMan 5.1 software (Nordic Cochrane Center, Copenhagen, Denmark) and STATA 11.0 software (Stata Corporation, College Station, TX).

Results

Trial Characteristics

Nine clinical trials including 1001 adult patients qualified for inclusion [8,11–14,19,20,25,26]. 468 patients were allocated to the corticosteroids groups, and 533 patients were allocated to the control groups. Among these trials, five were conducted in Europe, two in North America, one in Africa, and one in Asia. The mean age of the patients ranged from 34 to 72 years. Four trials specifically included severe CAP patients [8,11,14,25]. The remaining five trials included those with mild to severe CAP patients [12,13,19,20,26]. Four trials were multicenter RCTs [8,19,12,14]. The selected trials used various corticosteroids, including hydrocortisone, prednisolone, dexamethasone, and methyl-prednisolone. The durations of corticosteroids treatment ranged from 1 to 9 days. The characteristics of the trials are shown in Table 1.

Quality Assessment

We assigned an unclear risk of bias to one study [19] due to insufficient information regarding randomization and allocation. Despite two studies were open-label RCTs [20,26], we assigned a low risk of bias to them, as the lack of blinding would be unlikely to affect mortality. Double-blinded RCTs were assigned to a low risk of bias. Table 2 summarizes the risk of bias.
Primary Outcome

Data on mortality was available from eight trials (n = 970). Mortality was not significantly reduced by the use of corticosteroids (Peto OR 0.62, 95% CI 0.37–1.04; \( P = 0.07 \)) (Figure 2). There was low heterogeneity (\( I^2 = 13\% \)).

Secondary Outcomes

Four trials (n = 488) reported gastroduodenal bleeding events \([8,11,12,14]\). No significant difference was detected (Peto OR 1.67, 95% CI 0.41–6.80; \( P = 0.47 \); \( I^2 = 0\% \)). Three trials (n = 565) reported superinfection events \([8,12,13]\). There was also no difference (Peto OR 1.36, 95% CI 0.65–2.84; \( P = 0.41 \); \( I^2 = 71\% \)). Data on hyperglycemia events was available for three trials (n = 573) \([11–13]\). Corticosteroids was associated with more hyperglycemia events (Peto OR 2.64, 95% CI 1.68–4.15; \( P < 0.0001 \); \( I^2 = 0\% \)).

Subgroup Analysis

In the subgroup analysis by the severity (Figure 3), significant association was found among severe CAP patients and mortality (Peto OR 0.26, 95% CI 0.11–0.64; \( P = 0.003 \); \( I^2 = 0\% \)), but was not found among mild to severe CAP patients (Peto OR 0.95, 95% CI 0.50–1.78; \( P = 0.86 \); \( I^2 = 0\% \)). Subgroup analysis was also performed by duration of corticosteroids treatment. As shown in Figure 4, significant reduced mortality was found among patients with prolonged treatment (Peto OR 0.51, 95% CI 0.26–0.97; \( P = 0.04 \); \( I^2 = 37\% \)). However, the subgroup analysis of trials with shorter course failed to support the beneficial effect of corticosteroids in CAP (Peto OR 0.87, 95% CI 0.37–2.05; \( P = 0.75 \); \( I^2 = 0\% \)).

Sensitivity Analysis

The sensitivity analysis using the fixed-effects model yielded estimates similar to those of the Peto odds ratio for the risk of mortality (RR 0.63, 95% CI 0.38–1.04; \( P = 0.07 \); \( I^2 = 0\% \)).
sensitivity analysis using a random-effects model yielded estimates similar to those of the Peto odds ratio for the mortality risk (RR 0.73, 95% CI 0.43–1.23; \( P=0.23 \); \( I^2 = 0\% \)).

**Publication Bias**

The funnel plot for mortality showed slightly asymmetric (Figure 5). However, Egger's test did not indicate significant publication bias (\( P=0.556 \)).

**Discussion**

In this current meta-analysis of 9 RCTs including 1001 patients hospitalized for CAP, mortality was not significantly reduced by the use of corticosteroids. In the severe CAP subgroup, however, we observed a statistically significant decrease in mortality associated with the use of corticosteroids. There could be two potential reasons for the observed survival benefit. First, the immunomodulatory and anti-inflammatory effects of corticosteroids may damp or attenuate the inflammatory response due to severe CAP. Corticosteroids are the most powerful inhibitors of inflammation. They can switch on genes that encode anti-inflammatory cytokines and switch off genes that encode pro-inflammatory cytokines [27,28]. Second, in addition to the inflammatory response, the critical illness-related corticosteroid insufficiency (CIRCI) may play an important role in severe CAP. According to IDSA/ATS consensus guideline, CIRCI should be screened in all patients at risk for severe CAP [29]. In a systematic review, Salluh et al. [30] showed that the prevalence of CIRCI in severe CAP ranged from 0% to 48%. Cortisol is a major regulator in the immune system and inflammation. Therefore, corticosteroid

| Author/Year | Study Design | Location | No. Patients | Mean Age (y) | Patient Selection | Corticosteroids Used |
|-------------|--------------|----------|--------------|--------------|-------------------|---------------------|
| Wagner [19]/1956 | Quasi-RCT | USA | 113 | N/A | Mild to severe | Hydrocortisone, 560 mg, 5 d |
| McHardy [20]/1972 | Open-label RCT | UK | 126 | 60 | Mild to severe | Prednisolone, 20 mg/d, 7 d |
| Marik [25]/1993 | DB RCT | USA | 30 | 34 | Severe | Hydrocortisone, 10 mg/kg, 1 d |
| Confalonieri [8]/2005 | DB RCT | Italy | 48 | 64 | Severe | Hydrocortisone, 240 mg/d, 7 d |
| Mikami [26]/2007 | Open-label RCT | Japan | 31 | 72 | Mild to severe | Prednisolone, 40 mg/d, 3 d |
| Snijders [13]/2010 | DB RCT | Netherlands | 213 | 63 | Mild to severe | Prednisolone, 40 mg/d, 7 d |
| Meijvis [12]/2011 | DB RCT | Netherlands | 304 | 63 | Mild to severe | Dexamethasone, 5 mg/d, 4d |
| Sabry [14]/2011 | DB RCT | Egypt | 80 | 62 | Severe | Hydrocortisone, 300 mg/d, 7d |
| Fernández-Serrano [11]/2011 | DB RCT | Spain | 56 | 63 | Severe | Methyl-prednisolone, 620 mg, 9d |

DB, Double-Blinded; RCT, randomized controlled trial.

doi:10.1371/journal.pone.0047926.t001

| Author | Randomization method | Allocation concealment | Blinding of participants and personnel | Blinding of outcome assessment | Incomplete outcome data | Selective reporting | Other bias |
|--------|-----------------------|------------------------|--------------------------------------|-------------------------------|------------------------|-------------------|----------|
| Wagner [19] | Unclear risk | Unclear risk | Low risk | Low risk | Low risk | Unclear risk | Unclear risk |
| McHardy [20] | Low risk | Low risk | Low risk | Low risk | Low risk | Unclear risk | Unclear risk |
| Marik [25] | Low risk | Low risk | Low risk | Low risk | Low risk | Unclear risk | Unclear risk |
| Confalonieri [8] | Low risk | Low risk | Low risk | Low risk | Low risk | Unclear risk | Unclear risk |
| Mikami [26] | Low risk | Low risk | Low risk | Low risk | Low risk | Unclear risk | Unclear risk |
| Snijders [13] | Low risk | Low risk | Low risk | Low risk | Low risk | Unclear risk | Unclear risk |
| Meijvis [12] | Low risk | Low risk | Low risk | Low risk | Low risk | Unclear risk | Unclear risk |
| Sabry [14] | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |
| Fernández-Serrano [11] | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk | Low risk |

doi:10.1371/journal.pone.0047926.t002

Corticosteroids for CAP

PLOS ONE | www.plosone.org 4 October 2012 | Volume 7 | Issue 10 | e47926
replacement therapy might be effective in critical illness, including severe CAP. In subgroup analysis by the duration of corticosteroids treatment, we found that prolonged corticosteroids treatment (>5 days) was associated with a greater benefit compared with treatment courses less than 5 days. Recently, Annane et al. [23] assessed the use of corticosteroids for severe sepsis and septic shock in a systematic review. They showed that hydrocortisone for a prolonged duration (>5 days) may improve survival in severe sepsis and septic shock [23]. Moreover, a study on acute respiratory distress syndrome (ARDS) suggested that more than 7 days corticosteroids strategy led to reduction in markers of inflammation, duration of mechanical ventilation, and intensive care unit stay [31]. Therefore, the beneficial effect of prolonged corticosteroids treatment course on decreasing mortality in CAP cannot be excluded.

The potential side effects from corticosteroids in CAP should be clarified. Theoretically, corticosteroids could favor the onset of metabolic disorders, gastrointestinal bleeding, muscle weakness, and superinfection. Previous study found that corticosteroids increased the risk of hyperglycemia and hypernatremia [23]. In addition, there was no evidence for an increased risk of bleeding, superinfection, or neuromuscular weakness [23]. In our meta-analysis, treatment with corticosteroids in CAP was associated with an increased risk of hyperglycemia, but was not associated with gastrointestinal bleeding and superinfection. However, we could not address the association between treatment with corticosteroids and risk of hypernatremia or neuromuscular weakness. It was due to insufficient information can be extracted from primary publications. Further studies should be designed to analyze these issues. Hyperglycemia occurred frequently in corticosteroids treated patients. Berghe et al. [32] indicated that intensive blood glucose control reduced morbidity and mortality among critically ill patients. Therefore, the latest IDSA/ATS guideline suggested that close attention to tight glucose control was required, if CAP.

Figure 2. Meta-analysis for the association between mortality and corticosteroids.
doi:10.1371/journal.pone.0047926.g002

Figure 3. Subgroup analysis according to the severity of CAP.
doi:10.1371/journal.pone.0047926.g003
patients received corticosteroids [29]. A strict surveillance of control of blood glucose levels must be systematically conducted by physicians.

The results from meta-analyses could be influenced by publication bias. Egger’s test did not show significant publication bias. The asymmetric funnel plot, however, showed potential publication bias. Therefore, more studies are still needed to confirm the findings from this meta-analysis. Furthermore, there was no significant statistical heterogeneity in most of the comparisons. Thus, heterogeneity did not seem to have influenced the results. We also carried out a sensitivity analysis. The change of statistical models did not alter our conclusion of mortality, suggesting the reliability of this result.

Some limitations of this meta-analysis should be considered. First, the number of available studies that could be included in this meta-analysis was moderate. Therefore, the results could be
influenced by the factors like random error. Second, this study was a study-level meta-analysis but not an individual patient-level meta-analysis. It is known that study-level analyses can lead to biased assessments and use of aggregated summary values has some limitations for explaining the heterogeneity [33,34]. Third, because only studies that were indexed by the selected databases were included for data analysis, some relevant published studies or unpublished studies were missed, which may have biased our results.

In summary, although our overall results did not suggest a benefit for corticosteroids treatment in patients with CAP, analyses restricted to severe CAP patients or prolonged corticosteroids treatment showed a survival benefit. However, the number of studies only including severe CAP patients was small (4 studies, n = 214). Thus, large-scale, double-blind, placebo-controlled trials are still needed to evaluate the effects of corticosteroids in adults with severe CAP. A sensitive and validated formula to identify those who need corticosteroids in CAP patients is warranted. In addition, type of corticosteroids, the dosage, the duration, and tapering of the treatment, should be evaluated in rigorously designed and adequately powered RCTs in the future.

Author Contributions

Conceived and designed the experiments: WN QYX. Performed the experiments: WN YZ JWC. Analyzed the data: WN YZ JWC. Contributed reagents/materials/analysis tools: WN YZ JWC. Wrote the paper: WN YZ JWC.

References

1. Bartlett JG, Mundy LM (1995) Community-acquired pneumonia. N Engl J Med 333: 1618-1624.
2. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankvy SS, et al. (1996) Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 275: 134–141.
3. Endeman H, Meijvis S, Rijkers G, van Velzen-Blad H, van Moorsel C, et al. (2011) Systemic cytokine response in patients with community-acquired pneumonia. Eur Respir J 37: 1431–1438.
4. Martinez R, Menéndez R, Reyes S, Polverino E, Collinó C, et al. (2011) Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. Eur Respir J 37: 393–399.
5. Sibila O, Luna CM, Agustí C, Baquero S, Gando S, et al. (2008) Effects of glucocorticoids in ventilated piglets with severe pneumonia. Eur Respir J 32: 1037–1046.
6. Li Y, Cui X, Li X, Solomon SB, Danne RL, et al. (2008) Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model. Intens Care Med 34: 568–577.
7. Salluh JI, Verdeal JC, Mello GW, Araújo LV, Martins GAR, et al. (2006) Effects of systemic steroids in patients with severe community-acquired pneumonia. Intens Care Med 32: 595–598.
8. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, et al. (2005) Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 171: 242–249.
9. García-Vidal C, Calbo E, Pascual V, Ferrer C, Quintana S, et al. (2007) Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 30: 951-956.
10. Siempos II, Vardakas KZ, Kopterides P, Falagas ME (2008) Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother 62: 661-668.
11. Fernandez-Serrano S, Dorca J, Garcia-Vidal C, Fernandez-Sabe N, Carratalá J, et al. (2011) Effect of corticosteroids on the clinical course and outcomes of patients with severe community-acquired pneumonia: a randomized controlled trial. Crit Care 15:1–9.
12. Meijvis SCA, Hardeman H, Remmelts HH, Heijligenberg R, Rijkers GT, et al. (2008) Adjunctive therapies for community-acquired pneumonia: a systematic review. J Antimicrob Chemother 63: 1711–1723.
13. Endeman H, Meijvis S, Rijkers G, van Velzen-Blad H, van Moorsel C, et al. (2011) Systemic cytokine response in patients with community-acquired pneumonia. Eur Respir J 37: 393–399.
14. Sibila O, Luna CM, Agustí C, Baquero S, Gando S, et al. (2008) Effects of glucocorticoids in ventilated piglets with severe pneumonia. Eur Respir J 32: 1037–1046.
15. Li Y, Cui X, Li X, Solomon SB, Danne RL, et al. (2008) Risk of death does not alter the efficacy of hydrocortisone therapy in a mouse E. coli pneumonia model. Intens Care Med 34: 568–577.
16. Chen Y, Li K, Pu H, Wu T (2011) Corticosteroids for pneumonia. Cochrane Database Syst Rev 3: CD007720. DOI: 10.1002/14651858.CD007720.pub2.
17. Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org.
18. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6: e1000097.
19. Wagner JrHN, Bennett Jr IL, Lasagna L, Chief LE, Rosenbuhl MB, et al. (1956) The effect of hydrocortisone upon the course of pneumococcal pneumonia treated with penicillin. Bull Johns Hopkins Hosp 90: 197–215.
20. McHardy VU, Schreud M (1972) Amoxicillin dosage and use of prednisolone in treatment of pneumonia: a co-operative controlled trial. BMJ 4: 569–573.
21. Kirby JR, Polis G, Romansky MJ (1960) A controlled blind study of pneumococcal pneumonia treated with tetracycline and tetracycline plus 6-methyl prednisolone. Am J Med Sci 240: 64–69.
22. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A (2007) Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 26: 33–77.
23. Amann D, Bellissant E, Bollaert PE, Briel J, Confalonieri M, et al. (2009) Corticosteroids in the treatment of severe sepsis and septic shock in adults. JAMA 301: 2962–2973.
24. Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634.
25. Marik P, Kraus P, Selbhan J, Haslik I, Lipman J, et al. (1993) Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia: a randomized controlled study. Chest 104: 389–392.
26. Mikami K, Suzuki M, Kitagawa H, Kawakami M, Hirotta N, et al. (2007) Efficacy of corticosteroids in the treatment of community-acquired pneumonia requiring hospitalization. Lung 185: 249–255.
27. Rhen T, Cidlowski JA (2005) Antiinflammatory action of glucocorticoids—new mechanisms for old drugs. N Engl J Med 353: 1711–1723.
28. Galon J, Franchimont D, Hiroi N, Frey G, Boetnter A, et al. (2002) Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J 16: 61–71.
29. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell D, et al. (2007) Infections Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Supplement 2): S27–S72.
30. Salluh JIF, Shinotsuka CR, Soares M, Bozza FA, Laqa e Silva JR, et al. (2010) Cortisol levels and adrenal response in severe community-acquired pneumonia. J Crit Care 25 541: e1–e8.
31. Meduri GU, Marik PE, Chrousos GP, Pastores SM, Arlt W, et al. (2008) Steroid treatment in ARDS: a critical appraisal of the ARDS network trial and the recent literature. Intens Care Med 34: 61–69.
32. Van den Bergh G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, et al. (1993) Hydrocortisone and tumor necrosis factor in severe community-acquired pneumonia: a randomized controlled study. Chest 104: 389–392.
33. Higgins J, Thompson SG (2004) Controlling the risk of spurious findings from meta-analysis. Stat Med 23: 1359–1367.
34. Higgins J, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org.